peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes
Businessman gazing out the window

Vision, mission and strategy

Our vision  

A world where all patients with rare immunologic diseases can lead long and healthy lives. 

Our mission

We leverage our unique immunomodulating technology platform to develop innovative, lifesaving and life altering therapies, bring these to the patients with rare conditions who need them, and generate value to society at large.

Strategic priorities

Hansa’s mission is to become a global leader in rare diseases through the development of innovative, lifesaving and life altering treatments for patients with rare immunological conditions.

Commercialize IDEFIRIX® in first indication and markets

Successfully launch Hansa's first authorized product IDEFIRIX in Europe.

Secure FDA approval and launch  in the U.S.

Geographical Expansion.

Advance ongoing imlifidase clinical programs

Achieve approval/usage of imlifidase in follow-on indications

Broaden the label beyond kidney transplantation.

Expand IgG-cleaving enzyme technology

Expand IgG-cleaving enzyme technology platform into gene therapy.

Develop next generation IgG-cleaving enzymes for repeat usage

Build a focused, integrated, agile and empowered international organization and seek partnerships to accelerate growth and reduce risk

Søren Tulstrup, President and CEO, Hansa Biopharma

Hansa's pledge

Bringing our innovative science to those with urgent unmet medical needs

"Everything we do at Hansa Biopharma is driven by our mission in life: to develop lifesaving and life altering immunomodulating therapies, bring them to the patients with rare conditions who need them, and generate value to society at large."

Read more
vials seen from above